Cargando…
Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
INTRODUCTION: Alzheimer's disease (AD) diagnosis requires invasive CSF analysis or expensive brain imaging. Therefore, a minimal-invasive reliable and cost-effective blood test is requested to power large clinical AD trials at reduced screening failure. METHODS: We applied an immuno-infrared se...
Autores principales: | Nabers, Andreas, Hafermann, Henning, Wiltfang, Jens, Gerwert, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416642/ https://www.ncbi.nlm.nih.gov/pubmed/30911600 http://dx.doi.org/10.1016/j.dadm.2019.01.008 |
Ejemplares similares
-
Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019) -
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019) -
Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
por: O'Bryant, Sid E., et al.
Publicado: (2019) -
Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider
por: Zetterberg, Henrik, et al.
Publicado: (2019) -
Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
por: Liu, Shan, et al.
Publicado: (2019)